Teacher Retirement System of Texas reduced its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 70.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,750 shares of the company's stock after selling 11,513 shares during the quarter. Teacher Retirement System of Texas' holdings in Medpace were worth $2,668,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Quent Capital LLC purchased a new stake in shares of Medpace in the 3rd quarter worth about $25,000. Optiver Holding B.V. purchased a new position in shares of Medpace during the third quarter valued at about $27,000. Geneos Wealth Management Inc. raised its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after buying an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in Medpace in the fourth quarter worth about $30,000. Finally, Quarry LP purchased a new stake in Medpace in the third quarter worth about $35,000. 77.98% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several analysts have weighed in on the company. Wall Street Zen cut Medpace from a "buy" rating to a "hold" rating in a research report on Saturday. Weiss Ratings cut Medpace from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday, April 6th. Zacks Research lowered Medpace from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 12th. Jefferies Financial Group upgraded Medpace from a "hold" rating to a "buy" rating and set a $560.00 price objective for the company in a report on Friday, February 13th. Finally, TD Cowen raised Medpace from a "sell" rating to a "hold" rating and lowered their price objective for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $467.08.
Check Out Our Latest Analysis on MEDP
Insider Buying and Selling at Medpace
In other news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares of the company's stock, valued at $6,829,500. The trade was a 67.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 20.50% of the stock is owned by insiders.
Medpace Stock Performance
MEDP stock opened at $421.37 on Tuesday. The firm has a 50 day moving average price of $470.48 and a 200-day moving average price of $535.10. Medpace Holdings, Inc. has a 52-week low of $284.10 and a 52-week high of $628.92. The firm has a market capitalization of $12.03 billion, a price-to-earnings ratio of 26.48, a PEG ratio of 2.08 and a beta of 1.39.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts' consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm's revenue for the quarter was up 26.5% on a year-over-year basis. During the same quarter last year, the company earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.1 earnings per share for the current fiscal year.
About Medpace
(
Free Report)
Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
